Remote results of successful eradication Helicobacter pylori of patients with gastric ulcer (5-year follow-up)

Introduction. The Maastricht VI international guidelines define the most effective methods for diagnosing and treating H. pylori-associated peptic ulcer disease (PUD). Less attention has been paid to the subsequent course of PUD after successful eradication.

Aim. To evaluate the impact of successful H. pylori eradication on the subsequent course of gastric ulcer disease (GUD).

Materials and methods. Twenty patients with PUD after successful H. pylori eradication with a triple drug combination underwent annual EGDS for 5 years, including H. pylori biopsies, endoscopic pH monitoring, clinical dynamics, and blood gastrin and somatostatin levels.

Results. Over a 5-year observation period, disease recurrences were detected: by clinical manifestations – in 50% of cases (in 83% of cases, relapses were low-symptom or asymptomatic), by EGDS – in 60% of cases (of which ulcers were recorded in 15% of cases and gastric erosions in 45%). Recurrence of H. pylori infection was recorded in 45% of patients (of which 15% – with gastric ulcers and 30% – with gastric erosions), and in 15% of patients, the cause of gastric erosions was the use of NSAIDs; it was accompanied by weak to moderate degrees of H. pylori contamination and gastrointestinal tract inflammation.

Conclusion. A 5-year follow-up of PUD after successful eradication showed that H. pylori recurrence occurred in 45% of cases, with changes in the course of PUD. Benign (low-symptom and asymptomatic) recurrence was predominant, accompanied by mild to moderate H. pylori contamination and GM inflammation.

1. Ivashkin VT, Mayev IV, Lapina TL, Sheptulin AA, Trukhmanov AS, Baranskaya YeK et al. Diagnostics and treatment of Helicobacter pylori infection in adults: Clinical guidelines of the Russian gastroenterological association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2018;28(1):55–70. (In Russ). https://doi.org/10.22416/1382-4376-2018-28-1-55-70.

2. Malfertheiner P, Megraud F, Rokkas T, Gisbert JP, Liou JM, Schulz C et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022;71(9):1724–1762. https://doi.org/10.1136/gutjnl-2022-327745.

3. Malfertheiner P, Megraud F, O’Morain CA, Gisbert J P, Kuipers E J, Axon AT et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6–30. https://doi.org/10.1136/gutjnl-2016-312288.

4. Maev IV, Andreev DN, Samsonov AA, Cheryomushkina AS. Peptic ulcer: current state of the problem. Meditsinskiy Sovet. 2022;16(6):100–108. (In Russ.) https://doi.org/10.21518/2079-701X-2022-16-6-100-108.

5. Kayali S, Manfredi M, Gaiani F, Bianchi L, Bizzarri B, Leandro G et al. Helicobacter pylori, transmission routes and recurrence of infection: state of the art. Acta Biomed. 2018;89(8-S):72–76. https://doi.org/10.23750/abm.v89i8-S.7947.

6. Kim MS, Kim N, Kim SE, Jo HJ, Shin CM, Lee SH et al. Long-term follow-up Helicobacter pylori reinfection rate and its associated factors in Korea. Helicobacter. 2013;18(2):135–142. https://doi.org/10.1111/hel.12018.

7. Hu Y, Wan JH, Li XY, Zhu Y, Graham DY, Lu NH. Systematic review with meta-analysis: the global recurrence rate of Helicobacter pylori. Aliment Pharmacol Ther. 2017;46(9):773–779. https://doi.org/10.1111/apt.14319.

8. Zhao H, Yan P, Zhang N, Feng L, Chu X, Cui G et al. The recurrence rate of Helicobacter pylori in recent 10 years: A systematic review and meta-analysis. Helicobacter. 2021;26(6):e12852. https://doi.org/10.1111/hel.12852.

9. Minushkin ON, Osokina AP, Shuleshova AG, Shindina TS, Burdina EG. Remote results of successful eradication of Helicobacter pylori in patients with duodenal ulcer. Kremlin Medicine Journal. 2012;(1):123–126. (In Russ.) Available at: https://kremlin-medicine.ru/index.php/km/article/view/223.

10. Ford AC, Gurusamy KS, Delaney B, Forman D, Moayyedi P. Eradication therapy for peptic ulcer disease in Helicobacter pylori-positive people. Cochrane Database Syst Rev. 2016;4(4):CD003840. https://doi.org/10.1002/14651858.CD003840.pub5.

11. Lim NR, Kim J, Chung WC. Recurrence of Helicobacter pylori following successful eradication and clinical outcomes in Korean patients. Helicobacter. 2024;29(1):e13036. https://doi.org/10.1111/hel.13036.

12. Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D et al. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology. 2017;153(2):420–429. https://doi.org/10.1053/j.gastro.2017.04.022.

13. Zendehdel N, Nasseri-Moghaddam S, Malekzadeh R, Massarrat S, Sotoudeh M, Siavoshi F. Helicobacter pylori reinfection rate 3 years after successful eradication. J Gastroenterol Hepatol. 2005;20(3):401–404. https://doi.org/10.1111/j.1440-1746.2005.03561.x.

14. Axon AT, O’Moráin CA, Bardhan KD, Crowe JP, Beattie AD, Thompson RP et al. Randomised double blind controlled study of recurrence of gastric ulcer after treatment for eradication of Helicobacter pylori infection. BMJ. 1997;314(7080):565–568. https://doi.org/10.1136/bmj.314.7080.565.

15. Lazzaroni M, Perego M, Bargiggia S, Maconi G, Fiocca R, Solcia E et al. Helicobacter pylori eradication in the healing and recurrence of benign gastric ulcer: a two-year, double-blind, placebo controlled study. Ital J Gastroenterol Hepatol. 1997;29(3):220–227. Available at: https://pubmed.ncbi.nlm.nih.gov/9646213/.

16. Befrits R, Sjöstedt S, Tour R, Leijonmarck CE, Hedenborg L, Backman M. Long-term effects of eradication of Helicobacter pylori on relapse and histology in gastric ulcer patients: a two-year follow-up study. Scand J Gastroenterol. 2004;39(11):1066–1072. https://doi.org/10.1080/00365520410007872.

17. Ando T, Minami M, Mizuno T, Watanabe O, Ishiguro K, Ina K et al. Long-term follow-up after eradication of Helicobacter pylori with omeprazole, clarithromycin, and tinidazole (OCT regimen) in a Japanese population. Helicobacter. 2005;10(5):379–384. https://doi.org/10.1111/j.1523-5378.2005.00344.x

18. Daugule I, Ruskule A, Moisejevs G, Rudzite D, Jonaitis L, Janciauskas D et al. Long-term dynamics of gastric biomarkers after eradication of Helicobacter pylori infection. Eur J Gastroenterol Hepatol. 2015;27(5):501–505. https://doi.org/10.1097/MEG.0000000000000308.

19. Gisbert JP, Boixeda D, Al-Mostafa A, Vila T, de Rafael L, Alvarez Baleriola I et al. Basal and stimulated gastrin and pepsinogen levels after eradication of Helicobacter pylori: a 1-year follow-up study. Eur J Gastroenterol Hepatol. 1999;11(2):189–200. https://doi.org/10.1097/00042737-199902000-00022.

20. Bermejo F, Boixeda D, Gisbert JP, Sanz JM, Defarges V, Alvarez Calatayud G et al. Concentraciones basales de gastrina y pepsinógeno I y II en la úlcera gástrica: influencia de la infección por Helicobacter pylori y utilidad en el control de la erradicación [Basal concentrations of gastrin and pepsinogen I and II in gastric ulcer: influence of Helicobacter pylori infection and use-fulness in the control of the eradication]. Gastroenterol Hepatol. 2001;24(2):56–62. https://doi.org/10.1016/s0210-5705(01)78986-8.